Publications by authors named "Niall Treacy"

Article Synopsis
  • Recent advances in converting somatic cells into induced Pluripotent Stem Cells (iPSCs) have led to the development of kidney organoids for studying kidney development and disease.
  • Significant progress has been made by applying renal developmental signaling pathways and using hydrogel scaffolds like self-assembling peptide hydrogels (SAPHs) and gelatin methacryloyl (GelMA) for growing these organoids.
  • This work outlines methods to generate human iPSC-derived kidney organoids, their maturation in hydrogels, and protocols for characterizing these organoids through immunofluorescence imaging.
View Article and Find Full Text PDF
Article Synopsis
  • TGFβ1 regulates kidney cell fate and fibrosis progression.
  • SMAD3 and EZH2 co-occupy specific genomic regions in kidney stem cells and their derivatives.
  • Inhibiting EZH2 disrupts SMAD3 activity and prevents myofibroblast activation, highlighting a key mechanism in kidney fibrosis.
View Article and Find Full Text PDF
Article Synopsis
  • Human induced pluripotent stem cell (hiPSC)-derived kidney organoids show promise for disease modeling and personalized medicine, but improvements in their formation methods are needed.* -
  • Researchers matured these organoids in synthetic self-assembling peptide hydrogels (SAPHs) with varying stiffness, achieving structures similar to those grown in traditional animal-derived matrices like Matrigel.* -
  • Analysis revealed that organoids developed in higher stiffness SAPHs had more mature podocyte gene expressions and fewer off-target cell types, highlighting the benefits of using synthetic hydrogels for kidney organoid maturation.*
View Article and Find Full Text PDF

Cancer is predominantly a disease of older patients, with over half of those aged over 65 years of age being diagnosed with cancer at some stage. Despite comprising a significant proportion of the patients that we see in clinical practice, there is a lack of representation of older patients in cancer clinical trials. This is mainly due to restrictive trial inclusion criteria that prevent older patients from participating.

View Article and Find Full Text PDF